

## Extended Spectrum Beta-Lactamase production, Biofilm Formation and Antibiotic Resistance in Clinical Isolates of *Klebsiella pneumoniae*

Aisha Shitu Sa'id<sup>1\*</sup>, Mukhkar, M. D.,<sup>2</sup> Bukar, A.,<sup>2</sup> and Yusha'u, M.<sup>2</sup>

<sup>1\*</sup>Department of Microbiology, School of Life Sciences, Modibbo Adama University of Technology, Yola

<sup>2</sup>Department of Microbiology, Faculty of Basic Sciences, Bayero University Kano

\*Corresponding Author: ayshashitu@gmail.com; Mobile phone No: 07035818250

**Abstract:** *Klebsiella pneumoniae* is an opportunistic pathogen frequently multidrug-resistant, responsible for both health care and community associated infections. The appearance of extended-spectrum  $\beta$ -lactamase in addition to the biofilm-forming phenotype, is a major problem in the clinical environment. This study aimed to detect ESBL production, biofilm formation and antibiotic resistance profile of clinical isolates of *K. pneumoniae*. Three hundred and twenty five samples of urine and sputum were analyzed by conventional bacteriological techniques. Kirby-Bauer disc diffusion method was used for antimicrobial susceptibility testing. ESBL detection was done by the double-disc synergy tests using the Clinical and Laboratory Standards Institute guidelines. Biofilm formation was determined by microtiter plate assay. Out of the 325 samples analyzed, only 74 (22.7%) yielded *Klebsiella pneumoniae* isolates. Isolation rate was 25.5% for urine higher than that of sputum (20%). Isolates displayed 100% resistance to cefotaxime and ceftazidime and decreased resistance to imipenem and ciprofloxacin. ESBL production was observed in 31.1% of all the isolates. ESBL-producing isolates formed more biofilm than non ESBL producers. A significant association was observed between ESBL production and biofilm which may be as a result of uptake of ESBL carrying plasmids that activate the virulence factor. However, increased alertness of clinicians and enhanced testing by laboratories are important to reduce treatment failure and prevent the spread of resistance strains.

**Key words:** Antibiotic resistance; Biofilm formation; Extended Spectrum Beta lactamase; *Klebsiella pneumoniae*

### INTRODUCTION

Microorganisms growing in biofilms exhibit phenotypic characteristics that are distinct from those of planktonic organisms, including increased resistance to host immune defenses and to antimicrobial compounds (Stewart, 2002). The resistance could be due to the slowly growing state of the cells in the deeper layers of thick biofilms, which have less access to antibiotics and nutrients, and to the impaired diffusion of antimicrobial molecules within the biofilms (Ito et al., 2009; Hoiby et al., 2010). The possession of virulence traits particularly biofilm formation has aggravated the problem of *K. pneumoniae* antibiotic resistance. This poses a serious challenge to infection management worldwide and are likely to be associated with high level of morbidity, increased mortality, longer hospitalization and excessive health care costs compared with infections associated with antibiotic susceptible microorganisms (Hoiby et al.,

2010; Hou et al., 2015). This study aimed to detect ESBL production, biofilm formation and antibiotic resistance profile of clinical isolates of *K. pneumoniae*.

*Klebsiella pneumoniae* is an opportunistic pathogen correlated with both community and health care associated infections, such as pneumonia, urinary tract infections, septicemia, and wound infections worldwide and the main population at risk is the neonates and immunocompromised hosts (Podschun and Ullmann, 1998). The increasing frequency of multidrug-resistant *K. pneumoniae* has led to it being classified as a major public health concern (Cao et al., 2014). However, *K. pneumoniae* has become a clinically important microorganism, particularly in the last two decades due to its tendency to develop antibiotic resistance and cause fatal outcomes (Podschun and Ullmann, 1998; Nordmann et al., 2011). Beta-lactamase production by several gram negative and gram positive organisms is the

most important single mechanism of cephalosporins, monobactams and carbapenems (Chaudary and Aggarwal, 2004), which are the commonly used antimicrobials in treatment of bacterial infections in hospitals. Resistance to beta lactams antibiotics has become a growing problem in the treatment of nosocomial and community acquired infections caused by *K. pneumoniae* due to acquisition and expression of Extended Spectrum  $\beta$ -Lactamase. Extended-Spectrum Beta-lactamases (ESBLs) are a group of diverse, complex and plasmid-mediated rapidly evolving enzymes that pose a major therapeutic challenge in the treatment of patients (Bradford, 2001). They are able to inactivate beta-lactam antibiotics containing an oxyimino-group such as oxyimino-cephalosporins (e.g. ceftriaxone, cefotaxime, ceftazidime), oxyimino-monobactam (e.g. aztreonam) as well as the penicillins (Azekhume *et al.*, 2015). ESBLs are most commonly produced by *Escherichia coli* and *Klebsiella* species, with *Klebsiella pneumoniae* seemingly the major ESBL producer (Olowe *et al.*, 2011; Raji *et al.*, 2015). Extended Spectrum  $\beta$ -Lactamase *K. pneumoniae* turned into nosocomial pathogen of utmost significance in recent decades. It has not only disseminated extensively in hospitals but also acquired a variety of resistance mechanisms which turns it into a formidable infectious agent.

## MATERIALS AND METHODS

### Study Area

This study was carried out at the Federal Medical Centre, Yola. This hospital is a both referral and tertiary health facility located in Yola, the capital of Adamawa State, North-East region of Nigeria.

### Study Design

The study was cross sectional, hospital-based and descriptive in design carried out for a period of six months (February – August, 2018). A non-probability convenient type of sampling was used. Patients attending the out-patient clinics and in-patients at both hospitals were recruited into the study. They include patients from

resistance to penicillins, Paediatric wards, General Outpatient Department (GOPD), Medical and Antenatal clinic attendees. The patients were of different ages and sex. Sample size was determined using the formula derived by Cochran, with a 95% confidence interval, error margin of 5% and prevalence rate of 27% (from a study conducted Maiduguri on the prevalence of ESBL *K. pneumoniae*). The formula is as follows:

$$\text{Sample size (n)} = Z \times P \times (1 - P)/C^2$$

Where  $Z = 1.96$  (for 95% confidence level),  $C =$  Confidence interval (0.05) and  $P =$  prevalence rate of 27%

Ethical clearance was received from the Research Ethical Committee of Federal Medical Centre, Yola (Ref. No.: FMCY/SUB/96N/T/36). Samples from the participants were only included in the study after the consent was taken from each one of them. Any refusal to contribute the sample was well respected.

### Sample Collection and Identification

A total of 325 clinical samples of urine, sputum and nasal swabs were collected. The samples were collected from 165 and 160 patients with clinical evidence of urinary and respiratory tract infections respectively, as obtained by the physician from both General Out-patient Department (GOPD) and wards. The samples were immediately transported to the Microbiology laboratory for processing.

The organisms were isolated and identified by conventional bacteriological tests (Podschun and Ullaman, 1994; Collee *et al.*, 1996). Bacterial colonies with characteristic mucous and pinkish colour on MacConkey agar were presumptively identified as *Klebsiella* spp. Further confirmation was done by microscopy and biochemical tests using the API 20 E kit.

### Antibiotic Susceptibility Test

Antimicrobial susceptibility assay was performed according to Clinical Laboratory Standards Institute (CLSI) guidelines (CLSI, 2016) using the Kirby-Bauer disc diffusion method to evaluate the sensitivity of the test organisms. Antimicrobial agents used include ciprofloxacin (10  $\mu$ g), tazobactam-

piperacillin (10/100 µg), cefotaxime (30 µg), gentamicin (10 µg), nitrofurantoin (15 µg), aztreonam (30 µg), cefpodoxime (30 µg), ceftazidime (30 µg), imipenem (10 µg) and trimethoprim- sulfamethoxazole (1.25/23.75 µg) (Oxoid, UK). The result of the assay was interpreted according to the CLSI guidelines by measuring the diameter of the zone of inhibition that arise from diffusion of the agent into the medium surrounding the disk.

### Double Disk Synergy Test for ESBL Production

Isolates with zone diameters suspicious of ESBL production as predetermined by the susceptibility test results (Cefpodoxime:  $\leq 17$  mm; Ceftazidime:  $\leq 22$  mm; Cefotaxime:  $\leq 27$  mm) were subjected to the Double Disk Synergy Test (CLSI, 2016) to check for the presence of ESBL producing enzymes. Briefly, test organisms (suspected of ESBL production) were cultured overnight on nutrient agar, and a suspension prepared to match a 0.5 McFarland turbidity standard was inoculated onto the surface of each of the molten Mueller Hinton agar plates using a sterile cotton swab. Amoxicillin (20 µg)/ clavulanic acid (10 µg) combination disc was placed at the center of each inoculated Mueller Hinton agar plate. Cefotaxime (30 µg) and ceftazidime (30 µg) single discs were then placed 20 mm (center to center) from the amoxycillin/clavulanic acid disc and incubated at 37°C overnight (18-24 hrs). Enhancement of the zones of inhibition of any of the cephalosporin beta-lactam antibiotic discs towards the amoxycillin/clavulanic acid disc caused by the synergy with clavulanate was taken as an evidence of ESBL production. *K. pneumoniae* ATCC 700603 (ESBL-producer) was used as reference strain for quality control.

### Detection of Biofilm by Microtitre Method

Determination of biofilm production was carried out according to the procedure described by O'Toole and Kolter (1998). *K. pneumoniae* isolated from fresh agar plates

were inoculated in 10 mL of trypticase soy broth containing 1% glucose and incubated at 37°C for 24 h. The overnight cultures were then diluted in a ratio of 1:100 with fresh medium. Individual wells of sterile 96 well- flat bottom polystyrene tissue culture treated plates (Sigma- Aldrich, Costar, USA) were filled with 200 µL of the diluted cultures. The control organism was also incubated, diluted and added to tissue culture plate. Negative control wells contained inoculated sterile broth. The plates were incubated at 37°C for 24 h. After incubation, contents of each well were removed by gentle tapping and the wells were washed with 0.2 mL of phosphate buffer saline (pH 7.2) four times to remove free floating bacteria. Biofilm formed by bacteria adherent to the wells were fixed by 2% sodium acetate and stained with 0.1% crystal violet. Excess stain was removed by rinsing with deionized water and plates were kept for drying. Optical density (OD) of stained adherent biofilm was obtained by using micro ELISA autoreader (model 680, Biorad, UK) at wavelength 570 nm.

### Statistical Analysis

Data from the work were entered in the worksheet of Statistical Package for Social Science (SPSS) software version 25.0. Frequency and percentages were analyzed as descriptive findings. Inferential statistics were analyzed using Chi square test to find the association between ESBL producing *K. pneumoniae* and biofilm formation.

## RESULTS

The morphological characteristics and the biochemical test result of the *K. pneumoniae* isolates is summarized in Table 1a and 1b. Out of the overall 325 samples screened for the presence of *K. pneumoniae*, only 74 (22.7%) were positive. The rate of occurrence of the isolates was found to higher among those with urinary tract infections with frequency of 25.5% when compared to those with respiratory tract infections (20%) as shown in Table 2.

**Table 1a:** Colony characteristics of the *K. pneumoniae* isolates on MacConkey agar medium

| Colony Characteristics |                                |        |        |           |
|------------------------|--------------------------------|--------|--------|-----------|
| Size                   | Form                           | Colour | Margin | Elevation |
| Small                  | Circular (mucoid encapsulated) | Pink   | Entire | Raised    |

**Table 1b:** Analytical Profile Index test results of the isolates

| Test             | Result |
|------------------|--------|
| ONPG             | +      |
| ADH              | -      |
| LDC              | -      |
| ODC              | -      |
| CIT              | +      |
| H <sub>2</sub> S | -      |
| URE              | +      |
| TDA              | -      |
| IND              | -      |
| VP               | +      |
| GEL              | -      |
| GLU              | +      |
| MAN              | +      |
| SOR              | +      |
| RHA              | +      |
| SAC              | +      |
| MEL              | +      |
| AMY              | +      |
| ARA              | +      |
| INO              | +      |

**Key:** ONPG- O-Nitrophenyl-b-d-Galactopyranoside; ADH- Arginine dihydrolase; LDC- Lysine decarboxylase; ODC- Ornithine decarboxylase; CIT- Citrate; H<sub>2</sub>S- Hydrogen sulfide; URE- Urease; TDA- Tryptophan deaminase; IND- Indole; VP- Voges Proskauer; GEL- Gelatinase; GLU- Glucose; MAN- Mannose; INO- Inositol; SOR- Sorbitol; RHA- Rhamnose; SAC- Sucrose; MEL- Melibiose; AMY- Amygdalin; ARA- Arabinose

**Table 2:** Percentage occurrence of *K. pneumoniae* isolates among the clinical samples

| Samples collected | Site of infection | No. of isolates | % occurrence |
|-------------------|-------------------|-----------------|--------------|
| Sputum (n = 160)  | RTI               | 32              | 20           |
| Urine (n = 165)   | UTI               | 42              | 25.5         |
| Total (n = 325)   |                   | 74              |              |

Legends: RTI- Respiratory Tract Infections; UTI- Urinary Tract Infections; %- Percentage; n= number of samples

ESBL production was detected in 28 (37.7%) out of the 74 isolates recovered from the clinical samples. The results indicated that the isolates were able to enhance the inhibition zones of cefotaxime and ceftazidime on the site facing the amoxicillin-clavulanate disk. This enhancement toward towards the

amoxicillin-clavulanate disk was interpreted as a positive test (Plate 1).

The activities of the antibiotics tested against the ESBL producers are presented in table (3). All ESBL producing isolates showed resistance to cefotaxime and ceftazidime (100%), while lowest resistance was seen in imipenem (16.7%) and ciprofloxacin (20.5%).



**Plate 1:** A positive double disk synergy test for *K. pneumoniae* using cefotaxime disk, ceftazidime disk and amoxicillin clavulanate at the centre.


**Table 3:** Antibiotic Resistance Profile of ESBL Producing *K. pneumoniae*

| Antibiotics (µg)              | R(%) | S (%) |
|-------------------------------|------|-------|
| Ceftazidime                   | 100  | 0     |
| Cefotaxime                    | 100  | 0     |
| Cefpodoxime                   | 89.6 | 10.4  |
| Aztreonam                     | 78.4 | 21.6  |
| Imipenem                      | 16.7 | 83.3  |
| Ciprofloxacin                 | 20.5 | 79.5  |
| Gentamicin                    | 86.8 | 13.2  |
| Nitrofurantoin                | 35.3 | 64.7  |
| Piperacillin/Tazobactam       | 35.3 | 64.7  |
| Trimethoprim/Sulfamethoxazole | 74.6 | 25.4  |


Key: R: Resistance, S: Sensitive

Biofilm intensity was categorized as strong, moderate and weak. Optical densities (OD) of the isolates which were higher than biofilm negative control were considered as strong biofilm producers. Our findings indicated that out of the 28 ESBL *K. pneumoniae* isolates, 25 (93.9%) of ESBL producers were detected as strong biofilms, 2 (4.1%) as moderate biofilms and only 1 (2.0%) was found to be a weak or

nonbiofilm (Figure 1a). Moreover, strong biofilm production among the non ESBL producers was found to be 3 (9%), while 2(24%) of the non ESBL producers were showed to appear as moderate biofilm producers. Non biofilm production among the non ESBL producers 23(89%) was found to be higher compared to ESBL producers (Figure 1b).



**Figure 1a:** Biofilms formed with ESBL producing *K. pneumoniae*



**Figure 1b:** Biofilms formed with Non-ESBL producing *K. pneumoniae*

## DISCUSSION

*K. pneumoniae* have become major well recognized causative pathogens in both healthcare and community associated infections including respiratory and urinary tract infections and wound infections globally. They are among the major causes of preventable morbidity and mortality in developing countries where infection rates are fairly higher as a result of poor infection control practices, inadequate surveillances, congestion in hospitals and improper use of limited resources. In the present study, *K. pneumoniae* was mostly isolated from urine samples with highest prevalence rate of 25.5% in comparison with respiratory samples with 20%. Similar findings were reported by Giwa *et al.* (2018) from Northwestern Nigeria and Al-Yousef *et al.* (2016) from Saudi Arabia. In contrast, higher prevalence rate of 54.4% was reported by Akujobi (2007) in Ebonyi, 71.1% by Chibueze (2014) in Enugu while Ali and Ismael (2017) in Erbil city found a higher rate of 75.9% and a very low rate of 10% for urine and sputum respectively. Based on the result of this study, the overall prevalence of ESBL *K. Pneumoniae* was 37.7%. This study is similar to findings of Bajfal *et al.* (2014); Aggrawal *et al.* (2008); Akanbi *et al.* (2013) and Giwa *et al.* (2018) where ESBL production was found to be 34.3%, 36.8%, 33.6% and 34.4%

respectively. Several reports regarding the prevalence of ESBL producing *K. pneumoniae* have been documented all over the world (Al Jasser, 2006; Siraj *et al.*, 2014). The profile of the ESBL producing species may vary geographically particularly in isolates which are rapidly changing with time due to complex epidemiology of ESBLs and methods used for ESBL detection among other factors (Al-jasser *et al.*, 2006; Azekhueme *et al.*, 2015). However, in some studies from other part of Nigeria, Chikwendu *et al.* (2010), Ogefere *et al.* (2013), Yusha'u *et al.* (2010), Iroha *et al.* (2010), Azekhueme *et al.* (2015) in Calabar, Benin, Kano, Ibadan and Uyo respectively, recorded prevalence of 48.3%, 44.3%, 66.7%, 76.9% and 47.1%. The increased prevalence of ESBL *K. pneumoniae* in different regions of the world especially the developing countries of the world is disturbing. This problem may be as a result of multiple factors such as inappropriate use of antibiotics for febrile infections as well as limited infection control measures to reduce the spread of multidrug resistant strains. This reported prevalence differs with findings of some continental studies carried out in South America (18.1%), Asia-Pacific (14.2%), Europe (11%) and North America (7.5%) region (Hawser *et al.*, 2011; Siraj *et al.* 2014).

Perhaps, this high prevalence from our study as compared to other developed countries might be due to the fact that developed nations have strict infection management policies and practices, brief or average hospital stay, proper nursing barriers that can significantly reduce the chances of transmission and spread of ESBL producing strains (Azekhueme *et al.* 2015; Giwa *et al.* 2018).

All ESBL producing isolates showed maximum resistance to cefotaxime and ceftazidime (100%), while lowest resistance was seen in imipenem (16.7%). This agrees with studies reported by Raylane *et al.* (2018) and Yangzan *et al.* (2018) with resistance rate of 95.5% and 100% respectively for third generation cephalosporins. Commonly prescribed antibiotics in our community settings such as third generation cephalosporins, gentamicin, aztreonam and trimethoprim/sulfamethoxazole were among the least effective as seen in this study. The reason for such could be linked with increased misused and abuse of these cheap antibiotics which are easily accessible as over-the-counter (OTC) drugs and can even be taken without physician's prescription (Anikpo *et al.*, 2009).

Infections caused by ESBL producing *K. pneumoniae* are connected to harsh conditions due to expression of virulence features by these strains and have been reported to have major role in their pathogenicity (Sahly *et al.*, 2008). Furthermore, biofilms have the ability to protect bacteria from the effect of antimicrobials when compared with other nonbiofilm forming bacteria (Bellifa *et al.*, 2013). This current study revealed that

strong biofilm formation was noticed among ESBL producers (93%) when compared to for non ESBL producers (6.5%) with highly significant difference ( $P < 0.05$ ) (figure 1a and b). The results are in consistent with that of Gharrah *et al.* (2017) who reported that development of biofilms is found to be higher with ESBL producing *K. pneumoniae* strains than non ESBL producing strains. This high rate of biofilm formation among ESBL producing *K. pneumoniae* may be as a result of uptake of ESBL carrying plasmids which activate the virulence factor by upregulation of some genes or adding new virulence genes such as type 1 or type 3 fimbriae that are greatly responsible for invasion and biofilm production in *K. pneumoniae* (Vuotto *et al.*, 2014; Yazgan *et al.*, 2018).

## CONCLUSION

The present study clearly highlights that there is a strong relationship between ESBL production and biofilm formation which led to immense antibiotic resistance in *K. pneumoniae* isolates. All the isolated ESBL producers were resistant to third generation cephalosporins but are still sensitive to carbapenems like Imipenem. There is an alarming increase in resistance rate to a number of commonly used antibiotics. However, increased alertness of clinicians and enhanced testing by laboratories are important to reduce treatment failure and prevent the spread of ESBL producing *K. pneumoniae*. Furthermore, formation of a strict antibiotic policy in hospitals is also necessary as it will help in reducing the resistance level.

## REFERENCES

- Azekhueme, I., Moses, A. E., Abbey, S. D. (2015). Extended Spectrum Beta Lactamase in clinical isolates of *E. coli* and *K. pneumoniae*. *Journal of Advances in medical and pharmaceuticals*. 2(3): 17-25.
- Orsi, G.B., Falcone, M., Venditti, M. (2011). Surveillance and management of multidrug-resistant microorganisms. *Expert Review of Anti-Infective Therapy*; 9: 653-79.
- Chaudhary, U., Aggarwal, R. (2004). Extended spectrum Beta-lactamases (ESBL) – an emerging threat to clinical therapeutics. *Indian Journal of Medical Microbiology*; 22(2): 75-80.

- Bradford, P. A. (2001). Extended spectrum  $\beta$ -lactamases in the 21<sup>st</sup> century: characterization, epidemiology, and detection of this important resistance threat. *Clinical Microbiology Review*; 14: 933–51.
- Olowe, O. A., Oladipo, G. O., Makanjuola, O. A., and Olaitan, J. O. (2011). Prevalence of extended spectrum  $\beta$ -lactamases (esbls) carrying genes in *Klebsiella* spp. from clinical samples at Ile-Ife, South Western Nigeria. *International Journal of Pharmamedicine and Biological Science*.
- Raji, M.A., Jamal, W., Ojemeh, O., and Rotimi, V.O. (2015). Sequence analysis of genes mediating extended-spectrum  $\beta$ -lactamase (ESBL) production in isolates of *Enterobacteriaceae* in a Lagos Teaching Hospital, Nigeria. *BMC Infectious Diseases*; 15:259.
- Stewart, P.S. (2002). Mechanisms of antibiotic resistance in bacterial biofilms. *International Journal of Medical Microbiology*; 292: 107–13.
- Ito, A., Taniuchi, A., May, T. et al. (2009). Increased antibiotic resistance of *Escherichia coli* in mature biofilms. *Applied Environmental Microbiology*; 75: 4093–100.
- Hoiby, N., Bjarnsholt, T., Givskov, M. et al. (2010). Antibiotic resistance of bacterial biofilms. *International Journal of Antimicrobial Agents*; 35: 322–32.
- Hou, X., Song, X., Ma, X., Zhang, S., Zhang, J. (2015). Molecular characterization of multidrug-resistant *Klebsiella pneumoniae* isolates. *Brazilian Journal of Microbiology*; 46(3): 759–768.
- Podschun, R., Ullmann, U. (1998). *Klebsiella* spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clinical Microbiology Review*; 11: 589–603.
- Collee, J.G., Miles, R.S. and Watt, B. (1996). “Tests for identification of bacteria,” in *Mackie and McCartney Practical Medical Microbiology*, J.G. Collee, A.G. Fraser, B.P. Marmion, and A. Simmon, Eds., Churchill Livingstone, New York, NY, USA, 14<sup>th</sup> edition, Pp:131–149.
- Clinical and Laboratory Standard Institute, (2016). “Performance standards for antimicrobial susceptibility testing. Twenty-four Informational supplements,” *CLSI Document 2016; M100-S24*, CLSI, Wayne, Pa, USA, 2016.
- O’Toole, G.A., Kolter, R. (1998). Flagellar and twitching motility are necessary for *Pseudomonas aeruginosa* biofilm development. *Molecular Microbiology*; 30: 295–304.
- Gharrah, M. M., El-Mahdy, A. M., Barwa, R. F. (2017). Association between virulence factors and Extended Spectrum  $\beta$ -Lactamase compared to nonproducing isolates. *Hindawi interdisciplinary perspective of infectious disease*.
- Samuel, S., Kayode, O., Musa, O., Nwigwe, G., Aboderin, A., Salami, T., et al., (2010). Nosocomial Infections and the Challenges of Control in Developing Countries. *African Journal of Clinical and Experimental Microbiology*; 11(2).
- Manzoni, P., De Luca, D., Stronati, M., Jacqz-Aigrain, E., Ruffinazzi, G., Luparia, M., et al., (2013). Prevention of Nosocomial Infections in Neonatal Intensive Care Units. *American Journal of Perinatology*; 30(02):081–8.
- Akujobi, C.N. (2007). Antimicrobial Susceptibility Patterns of *Klebsiella* species from Ebonyi State Teaching Hospital, Abakaliki, Nigeria. *Journal of Clinical Practice*; 8 (2): 90–93.
- Nicole, A.C., Karen, R.G. and Monica, S. (2010). Molecular epidemiology of multidrug resistant extended spectrum  $\beta$ -lactamase producing *Klebsiella pneumoniae* at Jamaican hospital 2000–2004. *BMC Microbiology*; 10 (27): 149–1577.

- Chibueze, N. E. (2014). Epidemiology of *Klebsiella pneumoniae* infection in four specialist health institutions in Enugu urban, Enugu state, Nigeria. A dissertation presented to the department of medical laboratory sciences in partial fulfilment of the requirements for the award of masters of sciences in medical laboratory sciences (medical microbiology).
- Ali, A.F. and Ismael, R. M. (2017). Dissemination of *Klebsiella pneumoniae* and *Klebsiella oxytoca* harbouring blaTEM genes isolated from different clinical samples in Erbil city. *Diyala Journal of Medicine*; 12(2): 40-51.
- Al-Jasser, A.M. (2006). Review Article: Extended- spectrum Beta-lactamases (ESBLs): A Global Problem. *Kuwait Medical Journal*; 38:171-85.
- Siraj, S.M., Ali, S. and Wondafrash, B. (2014). Extended spectrum B-lactamase production and antimicrobial resistance in *Klebsiella pneumoniae* and *Escherichia coli* among inpatients and outpatients at Jimma University Hospital. *African Journal of Microbiology Research*; 8(43): 3687-3694.
- Bajpai, T., Pandey, M., Varma, M., Bhatambare, G.S. (2014). Prevalence of extended spectrum beta-lactamase producing uropathogens and their antibiotic resistance profile in patients visiting a tertiary care hospital in central India: Implications on empiric therapy. *Indian Journal of Pathology and Microbiology*; 57:407-12.
- Aggarwal, R., Chaudhary, U., Sikka, R. (2009). Detection of extended spectrum  $\beta$ -lactamase production among uropathogens. *Journal of Laboratory Physicians*; 1:7-10.
- Akanbi, B.O., Ojonuba, B.D., Njoku, R. (2013). Detection of Extended Spectrum  $\beta$ - Lactamase Producing *Klebsiella pneumoniae* and *Escherichia coli* in Two Hospitals in the Federal Capital Territory, Abuja, Nigeria. *Open Journal of Medical Microbiology*; 3:207-12.
- Hawser, S.P., Bouchillon, S.K., Hoban, D.J., Badal, R.E., Hsueh, P.R., Paterson, D.L. (2009). Emergence of high levels of extended-spectrum beta-lactamase producing gram-negative bacilli in the Asia Pacific region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007. *Antimicrobial Agents and Chemotherapy*; 53:3280-4.
- Chikwendu, C. I., Amadi, E. S., Obi, R. K. (2010). Prevalence and antimicrobial resistance in *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* isolates from non-clinical urine samples. *N Y Science Journal*; 3: 194-200.
- Ogefere, H.O., Aigbiremwen, P.A., Omoregie, R. (2015). Extended-spectrum beta-lactamase (ESBL)-producing gram-negative isolates from urine and wound specimens in a tertiary health facility in Southern Nigeria. *Tropical Journal of Pharmaceutical Research*; 14:1089-94.
- Yusha'u, M.M., Aliyu, H.M. .Kumurya, A.S., Suleiman, L. (2010). Prevalence of extended spectrum beta lactamases (ESBL) among members of Enterobacteriaceae in Murtala Mohammed specialist hospital Kano, Nigeria. *Bajopas*; 3(1): 169-77.
- Iroha, I.R., Amadi, E.S., Oji, A.E., Nwuzo, A.C., Ejike-Ugwu, P.C. (2010). Detection of Plasmid Borne Extended Spectrum Beta-Lactamase Enzymes from Blood and Urine Isolates of Gram-negative Bacteria from a University Teaching Hospital in Nigeria. *Current Research in Bacteriology*; 3:77-83.
- Yazgan, B., Türkel, I., Güçkan, R., Kılınc, C., Yıldırım, T. (2018). Comparison of biofilm formation and efflux pumps in ESBL and carbapenemase

- producing *Klebsiella pneumoniae*. *Journal of Infection in Developing Countries*; 12(3):156-163. doi:10.3855/jidc.9677.
- Arikpo, G., Eja, M., Enyi-Idoh, K. (2009). Self-Medication in Rural Africa: The Nigerian Experience. *The Internet Journal of Health*; 11(1). Accessed on: 09/12/2014.
- Sahly, H., Navon-Venezia, S., Roesler, L. et al., (2008). "Extended-spectrum  $\beta$ -lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in *Klebsiella pneumoniae*," *Antimicrobial Agents and Chemotherapy*; 52 (9): 3029–3034.
- Bellifa, S., Hassaine, H., Balestrino, D., Charbonnel, N., M'hamedi, I., Terki, I.K., Lachachi, M., Didi, W., Forestier, C. (2013). Evaluation of biofilm formation of *K. pneumoniae* isolated from medical devices at the University Hospital of Tlemcen, Algeria. *African Journal of Microbiology Research*; 7(49): 5558–5564.
- Vuotto, F. Longo, F., Balice, M.P., Donelli, G. and Varaldo, P.E. (2014). "Antibiotic resistance related to biofilm formation in *Klebsiella pneumoniae*," *Pathogens*; 3:743–758.
- Nordmann, P., Carrer A. (2011). CTX-M-15-producing *Klebsiella pneumoniae*: a change in the epidemiology of ESBL. *Pathol Biol (Paris)*; 59: e133–5.
- Giwa, F.J., Ige, O.T., Haruna, D.M., Yaqub, Y., Lamido, T.Z., Usman, S.Y. (2018) Extended-Spectrum beta-lactamase production and antimicrobial susceptibility pattern of uropathogens in a Tertiary Hospital in Northwestern Nigeria. *Annals of Tropical Pathology*; 9:11-6.
- Cao, X., Xu, X., Zhang, Z., Shen, H. et al. (2014). Molecular characterization of clinical multidrug-resistant *Klebsiella pneumoniae* isolates. *Annual Clinical Microbiology and Antimicrobial*; 13: 16.
- Al Yousef, S. A., Younis, S., Farrag, E., Sh. Moussa, H., Bayoumi, F. S. and Ahmed, M. A. (2016). Clinical and Laboratory Profile of Urinary Tract Infections Associated with Extended Spectrum  $\beta$ -Lactamase Producing *Escherichia coli* and *Klebsiella pneumoniae*. *Annals of Clinical & Laboratory Science*; 46(4):394-400.